Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer.
Find out more about us
29 December 2022
16 December 2022
24 November 2022
Find out more
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies
Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.
IMC AGM, Dec 2022IMC SDC-1801 CTA submission, Aug 2022BioTrinity, April 2022 IMC Half Year Results, Feb 2022
Share price dataRegulatory News Service (RNS)
Sareum LimitedUnit 2A, Langford ArchLondon Road, PampisfordCambridge CB22 3FXUnited Kingdom
tel: +44 (0) 1223 497700fax: +44 (0) 1223 497701
Full-year Results 2022 ¦
Annual Report 2022 ¦